22.1 C
New York
Tuesday, June 9, 2026

Tag: protocols

newssourceFORcompanyinformationcontent1marketreleases

ProLogium and OPmobility Sign MoU to develop next generation Solid-State Battery Modules for Mobility

From Cells to System Integration: Launching Joint Evaluation of Solid-State Battery Modules for EV Applications 
From Cells to System Integration: Launching Joint Evaluation of Solid-State Battery Modules for EV Applications

Bybit TradFi Doubles Down on Zero-Fee Stock CFD Trading: 0 Commission + 0 Swap Fee

DUBAI, UAE, June 9, 2026 /PRNewswire/ -- Bybit, the world's second-largest cryptocurrency exchange by trading volume, is making stock CFD trading completely free via...

DBV Technologies to Present New Positive Data from VITESSE Study and Preview Recently Initiated THRIVE Study at the EAACI Congress 2026

Châtillon, France, June 8, 2026

Zoooom Launches Stripe-Powered ‘Secure Payments’ for Private-Party Car Sales

New feature introduces verified wire, card, and Klarna installment options to eliminate...

Peptide Tracker Launches Full Visual Redesign and New Safety Features for Peptide Protocol Tracking

A Rebuilt iOS Experience Adds Multi-Compound Blends, Per-Compound Concentrations, and a Visual Dose Guide That Shows Exactly How Much to Draw and What You...

Vivos Therapeutics To Participate in the Small Cap Showcase & WTR Insights on June 9, 2026

Vivos Therapeutics To Participate in the Small Cap Showcase & WTR Insights on June 9, 2026

Tethis to launch SmartBioSurface® slides at EACR Conference

MILAN, June 8, 2026 /PRNewswire/ -- Tethis S.p.A., a pioneering life sciences and diagnostics company, today announces the commercial launch of SmartBioSurface slides, an...

A New Lease of Life: Stories of Hope, Survivorship and Second Chances with Apollo Hospitals

Cancer changes lives long before it changes medical reports.NEW DELHI , June 8, 2026 /PRNewswire/ -- It disrupts routines, alters plans, and tests families in...

Zealand Pharma announces Boehringer Ingelheim’s survodutide Phase III trial in people living with obesity showed targeted 34% visceral and 63% liver fat reduction, while...

Company announcement No. 21 / 2026

Boehringer Ingelheim’s survodutide Phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis, supporting...

Ingelheim, Germany - Boehringer Ingelheim today announced positive results from two global Phase III trials of its glucagon/GLP-1 dual agonist survodutide (BI 456906), SYNCHRONIZE-1 and SYNCHRONIZE-MASLD.2,4 The results demonstrate survodutide’s potential to reduce weight and therefore improve metabolic health in two distinct populations: adults living with obesity or overweight, without type 2 diabetes (SYNCHRONIZE-1),2 and adults with overweight or obesity with metabolic dysfunction-associated steatotic liver disease (MASLD) with evidence of inflammation and or fibrosis (SYNCHRONIZE-MASLD).4 Full results from SYNCHRONIZE-1 and SYNCHRONIZE-MASLD were presented today at the American Diabetes Association’s (ADA) 2026 Scientific Sessions and published simultaneously in The New England Journal of Medicine and Nature Medicine respectively.5,6

Bybit Launches IPO Express, Becoming One of First Centralized Crypto Exchanges to Offer Tokenized IPO Access, Starting With SpaceX

DUBAI, UAE, June 7, 2026 /PRNewswire/ -- Bybit, the world's second-largest cryptocurrency exchange by trading volume, today announced the launch of Bybit IPO Express,...

Xsolis, Inc. Provides Notice of Data Security Incident

FRANKLIN, Tenn., June 5, 2026 /PRNewswire/ -- Xsolis, Inc. ("Xsolis"), a vendor that provides case and utilization management services to healthcare organizations, today announced...

Grifols Supports AlphaDetect to Accelerate Detection of Alpha-1

The sponsorship will help expand proven strategies to consistently detect a genetic, irreversible, and progressive condition in patients with liver and/or lung disease.DURHAM, N.C.,...

Emerging Crypto Projects Focus on Infrastructure as AI Narrative Evolves Beyond Simple Token Hype

SACRAMENTO, Calif., June 05, 2026 (GLOBE NEWSWIRE) -- The intersection of artificial intelligence and blockchain technology is entering a critical maturation phase, where speculative narratives are increasingly being replaced by projects that prioritize tangible network infrastructure. Solana Unchained stands at the forefront of this shift, constructing a decentralized environment where native tokens are not merely held for appreciation, but are required to power essential software utilities. 

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsProtocols

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers